| Description |
Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)[1][2][3][4].
|
| Related Catalog |
|
| In Vitro |
Imvotamab (1-10000 pM) 对利妥昔单抗耐药 ramos 细胞具有杀伤作用[5]。 Imvotamab (0.1-1000 pM) 对 standard ramos 细胞具有杀伤作用[5]。 Imvotamab (1-1000 pM) 显著减少了细胞激素释放症候群中 IL-6、IL-2、IFNγ 和 TNFα 的含量[5]。
|
| In Vivo |
Imvotamab (0.001-10 mg/kg；单剂量) 显著减少了食蟹猴体内的 B 细胞百分比[5]。 Imvotamab (25 mg/kg) 在非人灵长类动物中促进了脾脏和淋巴组织中的 B 细胞耗竭，且没有显著的不良影响[5]。
|
| References |
[1]. Hernandez G H, et al. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies[J]. Blood, 2022, 140(Supplement 1): 6436-6438. [2]. Li K, et al. Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile[J]. Blood, 2022, 140(Supplement 1): 6010-6011. [3]. Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136: 45-46. [4]. Hart K C, et al. High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing[J]. Cancer Research, 2022, 82(12_Supplement): 4179-4179. [5]. Baliga R, et al. A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release[J]. Cancer Res, 2020, 80(16 Supplement): 5664-5664.
|
